It delivers an adequate dose to the target tumor while sparing healthy tissues and organs at risk around the tumor.

它向靶肿瘤提供足够的剂量，同时保护肿瘤周围处于危险中的健康组织和器官。

Lung cancer is currently the world's second most prevalent malignant tumor, with the highest mortality rate.

癌症是目前世界第二大恶性肿瘤，死亡率最高。

For instance, the company has developed digital management tools for early detection and intervention of tumor patients, as well as artificial intelligence-based digital pathology and imaging devices that can help doctors to make diagnosis and predict recovery.

例如，该公司开发了用于肿瘤患者早期检测和干预的数字管理工具，以及基于人工智能的数字病理和成像设备，可以帮助医生进行诊断和预测康复。

Moreover, Ozurdex, a treatment of retinal diseases, will be on display at the CIIE, while Skyrizi, a standout product in immunology, and Epkinly, a hematological tumor solution, will make their "China debut" at the event.

此外，治疗视网膜疾病的Ozurdex将在CIIE展出，而免疫学领域的杰出产品Skyrizi和血液肿瘤解决方案Epkinly将在活动中“首次亮相”。

Due to the location of the primary tumor, surgery is rarely an option, and patients with the localized disease are treated primarily with radiation and chemotherapy.

由于原发肿瘤的位置，手术很少是一种选择，局部疾病的患者主要接受放疗和化疗。

PD-1 therapeutics revolutionizes cancer treatment as they enable the immune system to activate and kill the tumor.

PD-1疗法彻底改变了癌症治疗，因为它们使免疫系统能够激活和杀死肿瘤。

Shanghai-based molecular diagnostic information provider OrigiMed, together with scientists from several Chinese hospitals, announced the results of a study on the genomic characteristics of Asian cancer populations — the largest comprehensive genome analysis from tumor tissues and matched blood specimens of its kind so far, offering significant implications for clinical decision-making of precision medicine in China.

上海的分子诊断信息提供商OrigiMed与来自多家中国医院的科学家一起宣布了一项关于亚洲癌症人群基因组特征的研究结果，这是迄今为止对肿瘤组织和同类匹配血液样本进行的最大规模的综合基因组分析，为中国精准医疗的临床决策提供了重要启示。

Through Next Generation Sequencing technology, they worked out the comprehensive sequencing and comparative analysis of the tumor samples, expounded the different genomic characteristics of cancer patients between the East and West, and provided important basic evidence for China's precision medicine industry to be in line with international practice.

他们通过下一代测序技术，对肿瘤样本进行了全面测序和对比分析，阐述了东西方癌症患者不同的基因组特征，为中国精准医疗产业与国际接轨提供了重要的基础证据。

Currently, it has more than 100 ongoing research programs in sectors including COVID-19 testing, respiratory tract pathogen detection, maternal and child health, blood checks and tumor detection.

目前，它在新冠肺炎检测、呼吸道病原体检测、母婴健康、血液检查和肿瘤检测等领域有100多个正在进行的研究项目。

The drug has also become the only PD-1 inhibitor approved for first-line treatment in five tumor types with high incidence in China, according to the companies.

据这些公司称，该药物也成为唯一一种获批用于中国五种高发肿瘤类型一线治疗的PD-1抑制剂。

Berry Oncology, a leading Chinese company in genetic testing and early screening of tumors, plans to launch an early cancer screening product within the year that is capable in detecting six prevalent tumor types in China at one time, according to a senior executive of the company on Wednesday.

贝瑞肿瘤是中国领先的基因检测和肿瘤早期筛查公司，该公司一位高管周三表示，该公司计划在年内推出一种癌症早期筛查产品，能够一次检测出中国六种流行的肿瘤类型。

Through improving screening performance and optimizing the so-called HIFI technology, its self-developed tumor testing technology, the company aims to detect more than 20 tumor types through one-time blood draw with the product in the future, Wu Jiayan, Head of Berry Oncology Institutes, told a media briefing.

Berry肿瘤研究所所长吴家燕在一次媒体吹风会上表示，通过提高筛查性能和优化所谓的HIFI技术，即其自主研发的肿瘤检测技术，该公司的目标是在未来通过该产品一次性抽血检测20多种肿瘤类型。

It has published performance data of early screening with the HIFI system for liver cancer and multiple tumor types that include lung, gastric, colorectal, esophageal and pancreatic cancer.

它已经发表了HIFI系统对癌症和多种肿瘤类型（包括肺癌、胃癌、结直肠癌、食管癌和癌症）进行早期筛查的性能数据。

Sensitivity and specificity of early screening for liver cancer reached 95.42 percent and 97.91 percent respectively, and sensitivity and specificity of early screening for multi tumor types reached 87.58 percent and 99.09 percent, respectively.

癌症早期筛查的敏感性和特异性分别达到95.42%和97.91%，多种肿瘤类型早期筛查的灵敏度和特异性则分别达到87.58%和99.09%。

According to a report by Guosen Securities, global next-generation sequencing markets for tumors will grow at a compound annual rate of 27 percent to reach $75 billion in 2035, among which the early tumor detection market will grow at 75 percent a year on average to cover a population of 150 million.

根据国信证券的一份报告，全球下一代肿瘤测序市场将以27%的复合年增长率增长，到2035年将达到750亿美元，其中早期肿瘤检测市场将以75%的平均年增长率覆盖1.5亿人口。

Experts said that hematologic tumor patients are often at risk of relapse or even multiple relapses.

专家表示，血液肿瘤患者往往有复发甚至多次复发的风险。

Experts said the tumor subtype that the drug is indicated for treatment is a dangerous one.

专家表示，该药物用于治疗的肿瘤亚型是一种危险的亚型。

"Also, surufatinib is so far the only small-molecule targeted therapy that addresses all NET patients regardless of the origin of the tumor, and we believe that this drug will benefit many patients," he said.

他说：“此外，苏鲁法替尼是迄今为止唯一一种针对所有NET患者的小分子靶向治疗方法，无论肿瘤的起源如何，我们相信这种药物将使许多患者受益。”。

By engineering and developing therapeutic antibody candidates to selectively activate in the tumor microenvironment, the platform is designed to improve safety and tolerability of antibody therapeutics while maintaining clinical activity.

通过设计和开发治疗性候选抗体以在肿瘤微环境中选择性激活，该平台旨在提高抗体治疗的安全性和耐受性，同时保持临床活性。

The United States Food and Drug Administration on Monday approved CAR-T, a tumor immunotherapy, to treat adults with multiple myeloma.

美国食品和药物管理局周一批准了CAR-T，一种肿瘤免疫疗法，用于治疗成人多发性骨髓瘤。

The medicine was a potentially best-in-class innovative tumor drug developed by Nanjing-based Legend Biotech.

该药物是南京传奇生物技术有限公司开发的一种潜在的同类最佳创新肿瘤药物。

With proper and personalized pretreatment for tumor reduction and effective control of the disease in the CNS, patients with CNS involvement are no longer problem in CAR T-cell therapy.

通过适当和个性化的肿瘤减少预处理和中枢神经系统疾病的有效控制，中枢神经系统受累的患者在CAR T细胞治疗中不再是问题。

Under the agreement, the two companies will jointly invest capital, and will work together to develop and validate the personalized solid tumor MRD assays for cancer monitoring and recurrence in China.

根据协议，两家公司将共同投资，并将共同开发和验证用于中国癌症监测和复发的个性化实体瘤MRD检测。

These assays will be developed based on the genetic analysis of the primary tumor from individual patients at the beginning of treatment.

这些检测将在治疗开始时根据个体患者原发肿瘤的基因分析进行开发。

For solid tumor clinical trials in China that incorporate the use of NGS-based personalized MRD tests, AstraZeneca plans to incorporate the co-developed MRD test in China-specific studies, subject to fulfillment of individual study criteria.

对于在中国进行的包含基于NGS的个性化MRD测试的实体瘤临床试验，阿斯利康计划在符合个人研究标准的情况下，将共同开发的MRD测试纳入中国特定研究。

Cervical cancer is the third most common malign tumor among Chinese women aged 15 to 44, according to a research report in October by the HPV Information Center under the auspices of the WHO.

根据世界卫生组织赞助的HPV信息中心10月份的一份研究报告，癌症是中国15-44岁女性中第三常见的恶性肿瘤。

In the case of MSD, its cancer immunotherapy has been approved through eight indications in China from its first approval in 2018, covering five tumor types.

The company's more than 10 innovative molecules in discovery, with focus on innate immunity and tumor microenvironment, competed with an innovative antibody drug treating tumors.

Founded in August 2017, the company grew out of the tumor business unit of Berry Genomics, one of China's largest companies in genetic testing, and has since established a wide range of genetic testing products and services for tumor patients and high-risk groups.

The company said it has cooperated with more than 700 hospitals nationwide to provide genetic testing services for more than 100,000 tumor patients.

Official statistics show that new breast cancer cases in China numbered more than 410,000 last year, making it the fourth largest malignant tumor in terms of new incidence figures.

Cheng Shujun, an academician of the Chinese Academy of Engineering and a well-known tumor etiology expert, and Liu Lisheng, former president of the World Hypertension League and a renounced cardiologist, were announced as the chief consultants to serve on the committee during a ceremony held on Wednesday in Beijing.

United States-based Eli Lilly and Innovent, a domestic pharmaceutical company, jointly announced on Sunday the China market launch of a PD-1 inhibitor to be used for the indication of a main type of non-small cell lung cancer, a major tumor species threatening people's health in China and worldwide.

Lung cancer is the No 1 malignant tumor regarding both incidence and mortality rates in China.

Zhang Li, leader on the research group of the Phase-III clinical trials of the drug, said that this injection prolonged patients' progression-free survival for nearly nine months and reduced their risk of tumor progression by more than half.

The salon invited children with neuroblastoma and their families, healthcare professionals, public welfare organizations and government authorities, to discuss the solution to cure the disease — a tumor that occurs in children.

Although neuroblastoma is an overwhelming rare tumor, it is curable.

"Liver cancer is the fourth most common and the second most deadly malignant tumor seen in China.

Tislelizumab is the first drug from BeiGene's immuno-oncology biologics program and is being developed globally for the treatment of a broad array of both solid tumor and hematologic cancers.

Berry Oncology, a subsidiary of China's leading gene sequencing company, announced Monday findings of a clinical research it initiated got published on Cell Research, marking a milestone in its development of a so-called HIFI tumor testing technology used in the research on early detection of liver cancer in cirrhotic patients.

The company said the technology-empowered products will be available for lung and other cancers in a few years to help the company take an early grip of the billion-dollar early tumor detection market in China.

According to a report by Guosen Securities, global next-generation sequencing markets for tumors will grow at a compound annual rate of 27 percent to reach $75 billion in 2035, among which the early tumor detection market will grow at 75 percent on average a year to cover a population of 150 million.

"Surufatinib has the potential to become the first approved therapy to address all NET patients regardless of the tumor origin.

"Compared with other NET therapies available in the market, surufatinib has a unique dual mode of action by both inhibiting angiogenesis and promoting the body's immune response against tumor cells.

Chen Kaixian, an academician with the Chinese Academy of Sciences, said the market launch of the medicine, the company's second oncology drug approved in China, provides a new solution to neuroendocrine tumor treatment.

Lymphoma, a malignant tumor that originates from the lymphoid hematopoietic system, is one of the top 10 malignant tumors with the highest mortality rates in China.

"We are building a comprehensive medical AI portfolio including Tencent AIMIS, the Guide and Assistant Diagnosis System, and the Tumor Assistant Diagnosis System, which have proven the feasibility of combining AI with medical treatments.

Sean Shan, president of Takeda China, said that an innovative therapy treating multiple myeloma, the second most common malignant tumor in the blood system, obtained regulatory approval in April last year and was launched on the market in July 2018, a year in advance from the company's estimated timeframe thanks to the healthcare reforms.

A supporting tumor gene detection kit for the system has also been successfully developed, which can be adapted to many types of samples from tissues to body fluids, including glioma, lung, urothelial, breast and thyroid cancers, covering the fields of early screening, molecular pathology diagnosis and medication guidance, the company said.

Because of the high heterogeneity of its tumor cells, TNBC has very high invasiveness, recurrence rate and metastasis, and lacks an effective targeted therapy.

Compared with conventional radiotherapy, proton beams will only release a large percentage of radiation dose when they reach a tumor, which means it will kill the cancer cells while leaving healthy cells intact, according to Zhang.

The company has been developing an immune cell therapy product based on a method called Expanding Activated Lymphocytes to treat solid tumor, and the clinical trial is designed to access the therapy's ability to prevent recurrence after radical surgery of liver cancer, one of the top cancer killers in China.

Philips (China) Investment Co Ltd and the China Strategic Alliance of Industry Technology Innovation for Minimal Invasive Tumor Therapy, the only national association approved by the Ministry of Science in the field of clinical medicine, signed a strategic cooperation agreement on Tuesday in Beijing to promote minimal invasive tumor ablation treatment.

The two sides will also work together to promote minimal invasive ablation therapy-based diagnosis and treatment standards for tumor care, as well as organizing training programs for doctors in remote and underprivileged areas.

He hopes the cooperation between the alliance and Philips will help promote minimal invasive ablation tumor therapy and early detection-based cancer care in China, as well as promote a healthy lifestyle.

Since BMS entered the Chinese market 30 years ago, it has launched about 40 prescription and non-prescription medicines, covering the treatment fields of chronic heptatis B, cardiovascular disease, diabetes, tumor and antibiotics, the company's statement said.

For instance, the foundation has set up a research group for tumor prevention and control center at Sun Yat-sen University in Guangzhou, Guangdong province.

A hospital specializing in tumor treatment will be set up to offer comprehensive nursing care for the local community, it said.

"Hogg explained that the way the drug works is by preventing tumor cells from dividing.

""So what this molecule that we've made does is it stops the tumor cells from metabolising the sugar in the way that they want and as a result, they can't divide and then if that block goes on for long enough they die.

The checkup includes all the regular ones such as blood tests and urine analysis, as well as the less common PET-CT examinations for tumor markers.

We continue to pay attention to the process of incorporating targeted tumor drugs into the national essential medicines list — including gene testing for targeted tumor therapy added to national medical insurance, further optimization of China's medical policies on assisted reproduction, institutionalized thyroid screening for women of childbearing age and digital whole-course diabetes management.

Inkon Life, another subsidiary of Haier Group that provides tumor radiation therapy equipment and tumor medical care services, said its total revenue stood at 1.16 billion yuan in 2022, up 6.09 percent year-on-year.

"The plan will inject new impetus to China's bioeconomy growth, including fields such as early tumor detection," said Oscar Zhang, a principal at Qiming Venture Partners.

Currently in the preclinical stage, the molecule cross-links tumor cells and T cells by targeting a specific tumor-associated antigen and a protein complex and thus leads to potent T cell activation to fight the tumor.

"Periodic results have been achieved in the tumor, immunity, central nervous system, metabolism and cardiovascular fields from existing collaboration with Chinese hospitals," said Zhang Wei, head of medicine at Boehringer Ingelheim.

It claimed it has cooperated with more than 700 hospitals nationwide to provide genetic testing services for more than 100,000 tumor patients.

The company claimed its product can detect early tumor changes six to 12 months before traditional testing methods, saving valuable time for medical intervention.

They include a PD-1 antibody for tumor immunotherapy, a tumor-targeting drug and a PARP inhibitor also used for cancer treatment.

Domestic gene technology firm Burning Rock, dedicated to R&D of tumor testing, was listed on the Nasdaq last year after its establishment in 2014.

Focusing on the innovative pharmaceutical industry and its role in the implementation of the Healthy China 2030 initiative, the report said about 33 percent of innovative drugs approved in the past five years are tumor treatments, and about 80 percent of the drugs, or 156 titles, are from multinational pharmaceutical companies.

The innovative drugs registered by multinational pharmaceutical companies have also showed more diversity in the past five years, as the share of tumor treatments has dropped to 33 percent from 47 percent in the period from 2010 to 2015, while more drugs for diseases related to the nervous system, digestion and the cardiovascular and respiratory systems have been registered.

The company now owns an 8,000 sq m manufacturing base for developing Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T)－a tumor immunotherapy mainly applied to leukemia and lymphoma－and has so far obtained 3 CAR-T official approvals to initiate clinical trials.

Medlinker has signed a strategic cooperation agreement with Chia Tai Tianqing Pharmaceutical Group to jointly tap potentials in the chronic disease management, including innovative patient care models in sectors such as tumor, liver and respiratory diseases.

Apart from the company's key business areas, including oncology, tumor immunization and immuneregulation, the external innovation hub will also look into novel fields representing needs and orientations in the future, such as anti-infection, regenerative medicine and gene therapy modalities, she said.

Most of the license-in programs were for tumor treatments, and the rest were in fields such as artificial intelligence drug development, ophthalmology and cell therapy.

The license-out programs mainly involved areas such as tumor treatment, neurological medicines, immunotherapy and blood lipid control.

A tumor patient database can be established and the most standardized models of diagnosis and treatment of certain types of cancer will be formed, Li said, thus establishing a system to guide every step in a doctor's decision-making process when making a diagnosis.

The FDA said 84 percent of patients had tumor shrinkage with a median duration of response (time between the initial response to therapy and subsequent disease progression or relapse) of 19.5 months, in a single-arm clinical trial of Brukinsa including 86 patients with MCL who received at least one prior treatment.

The trial was supported by an additional single-arm trial that included 32 patients, in which 84 percent of patients had tumor shrinkage with a median duration of response of 18.5 months.

In the trial, 84 percent of patients had tumor shrinkage with a median duration of response (time between the initial response to therapy and subsequent disease progression or relapse) of 19.5 months.

A report published by Chyxx, an online industry information network, estimated that by 2025, the market volume of China's tumor gene sequencing, which is part of precision medicine, will reach 48 billion yuan.

Li Wenbin, deputy chief of the glioblastoma multiforme branch of the China Anti-Aancer Association, said Optune, a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die, will probably be approved for commercialization in the Chinese mainland within the year, marking a milestone of progress for the disease care.

Entrepreneurs invited to a panel discussion during the release ceremony of the white paper included Gong Zhaolong, CEO of 3DMed, and former senior review expert of the United States Food and Drug Administration, and ChengZheng, chairman and president of Beijing Allcure Medical Technology Co Ltd, which focuses on providing services to hospitals regarding tumor detection and treatment.

For example, a customer with a family history of lung cancer should include a chest CT scan, while those over 50 years old should select tumor screening.

In Shanghai's Huashan Hospital, VR has already been used in endoscopic surgery to remove a brain tumor from a patient.

In 2019, a surgeon at Shanghai-based Huashan Hospital performed an endoscopic surgery to remove a pituitary tumor in a patient's brain.

On Jan 17 this year, surgeons at Huashan Hospital made an attempt to excise a basicranial tumor, bolstered by 5G mixed reality (MR) technology developed by a Shanghai-based startup.

Tislelizumab is the first drug from BeiGene's immuno-oncology biologics program and is being developed globally as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.

The newly approved indication, for patients suffering from locally advanced or metastatic urothelial carcinoma with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, is the first in a solid tumor indication.

With tislelizumab's first solid tumor approval, we are even more excited about the outlook for this immunotherapy than ever.

The Party considers corruption a tumor threatening its very health.